Altered oxidative neurometabolic response to methylene blue in bipolar disorder revealed by quantitative neuroimaging
Journal of Affective Disorders · 2024
DOI: 10.1016/j.jad.2024.07.029 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2024. Verfasst von Alfonso Russo und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, UK; Sussex Partnership NHS Foundatio…. Hauptthemen laut MEDLINE: Bipolar Disorder, Magnetic Resonance Imaging, Methylene Blue. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Cerebral mitochondrial and hemodynamic abnormalities have been implicated in Bipolar Disorder pathophysiology, likely contributing to neurometabolic vulnerability-leading to worsen clinical outcomes and mood instability. To investigate neurometabolic vulnerability in patients with BD, we combined multi-modal quantitative MRI assessment of cerebral oxygenation with acute administration of Methylene Blue, a neurometabolic/hemodynamic modulator acting on cerebral mitochondria. METHODS: Fifteen euthymic patients with chronic BD-type 1, and fifteen age/gender-matched healthy controls underwent two separate MRI sessions in a single-blinded randomized cross-over design, each after intravenous infusion of either MB (0.5 mg/kg) or placebo. MRI-based measures of Cerebral Blood Flow and Oxygen Extraction Fraction were integrated to compute Cerebral Metabolic Rate of Oxygen in Frontal Lobe, Anterior Cingulate, and Hippocampus-implicated in BD neurometabolic pathophysiology. Inter-daily variation in mood rating was used to assess mood instability. RESULTS: A decrease in global CBF and CMRO2 was observed after acutely administrating MB to all participants. Greater regional CMRO2 reductions were observed after MB, in patients compared to controls in FL (mean = -14.2 ± 19.5 % versus 2.3 ± 14.8 %), ACC (mean = -14.8 ± 23.7 % versus 2.4 ± 15.7 %). The effects on CMRO2 in those regions were primarily driven by patients with longer disease duration and higher mood instability. LIMITATIONS: Sample size; medications potentially impacting on response to MB. CONCLUSIONS: An altered neurometabolic response to MB, a mitochondrial/hemodynamic modulator, was observed in patients, supporting the hypothesis of vulnerability to neurometabolic stress in BD. Integrating quantitative imaging of cerebral oxygen metabolism with a mitochondrial-targeting pharmacological challenge could provide a novel biomarker of neurometabolic and cerebrovascular pathophysiology in BD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neuroscience, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, UK; Sussex Partnership NHS Foundation Trust, Worthing, UK. Electronic address: A.Russo@bsms.ac.uk.
- Department of Clinical Neuroscience, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, UK; Radiology, Leiden University Medical Center, Leiden, the Netherlands.
- Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
- School of Engineering and Informatics, University of Sussex, Falmer, Brighton, UK.
- Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.
- Department of Clinical Neuroscience, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, UK.
Zitieren
APA
Russo, A., Örzsik, B., Yalin, N., Simpson, I., Nwaubani, P., Pinna, A., De Marco, R., Sharp, H., Kartar, A., Singh, N., Blockley, N., Stone, A. J. L., Turkheimer, F. E., Young, A. H., Cercignani, M., Zelaya, F., Asllani, I., & Colasanti, A. (2024). Altered oxidative neurometabolic response to methylene blue in bipolar disorder revealed by quantitative neuroimaging. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.07.029
Vancouver
Russo A, Örzsik B, Yalin N, Simpson I, Nwaubani P, Pinna A, et al. Altered oxidative neurometabolic response to methylene blue in bipolar disorder revealed by quantitative neuroimaging. Journal of Affective Disorders. 2024. doi:10.1016/j.jad.2024.07.029
BibTeX
@article{Russo2024,
author = {Russo, Alfonso and Örzsik, Balázs and Yalin, Nefize and Simpson, Ivor and Nwaubani, Prince and Pinna, Antonello and De Marco, Riccardo and Sharp, Harriet and Kartar, Amy and Singh, Nisha and Blockley, Nicholas and Stone, Alan John Luke and Turkheimer, Federico E and Young, Allan H and Cercignani, Mara and Zelaya, Fernando and Asllani, Iris and Colasanti, Alessandro},
title = {Altered oxidative neurometabolic response to methylene blue in bipolar disorder revealed by quantitative neuroimaging},
journal = {Journal of Affective Disorders},
year = {2024},
doi = {10.1016/j.jad.2024.07.029}
}
EUVIMED